Literature DB >> 1168252

Quantification of the analgesic activity of narcotic antagonists by a modified hot-plate procedure.

J P O'Callaghan, S G Holtzman.   

Abstract

The analgesic activity of morphine and the narcotic antagonists, pentazocine, cyclazocine, levallorphan and nalorphine, was assessed in the rat using two hot plates: one maintained at 49.5 degrees C and the other at the "standard" 54.5 degrees C. The analgesic effects of morphine using the 49.5 degrees C hot plate were of a significantly greater magnitude than its effects using the 54.5 degrees C hot plate for both nontolerant and morphine-tolerant subjects. Dose-related effects were observed with all of the narcotic antagonists tested using the 49.5 degrees C hot plate; only the highest dose of pentazocine exhibited activity using the 54.5 degrees C hot plate. Naloxone (3.0 mg/kg) antagonized the analgesic effects of morphine and all of the narcotic antagonists, but was without activity itself when tested using the 49.5 degrees C hot plate at doses as high as 30 mg/kg. Aspirin was also inactive using the 49.5 degrees C plate, whereas physostigmine increased latencies only at a dose that produced severe motor deficit. A low temperature hot plate is recommended for evaluating the analgesic activity of narcotic antagonists in the rat. This simple procedure provides results which are dose-related, quantifiable, reproducible, of a large magnitude and specific.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1168252

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  47 in total

1.  Role of CD38, a cyclic ADP-ribosylcyclase, in morphine antinociception and tolerance.

Authors:  Lynn C Hull; Christopher Rabender; Bichoy H Gabra; Fan Zhang; Pin-Lan Li; William L Dewey
Journal:  J Pharmacol Exp Ther       Date:  2010-06-15       Impact factor: 4.030

2.  Abnormal development of the locus coeruleus in Ear2(Nr2f6)-deficient mice impairs the functionality of the forebrain clock and affects nociception.

Authors:  Marei Warnecke; Henrik Oster; Jean-Pierre Revelli; Gonzalo Alvarez-Bolado; Gregor Eichele
Journal:  Genes Dev       Date:  2005-03-01       Impact factor: 11.361

3.  A critical analysis of the experimental evaluation of nociceptive reactions in animals.

Authors:  K Ramabadran; M Bansinath
Journal:  Pharm Res       Date:  1986-10       Impact factor: 4.200

4.  A classification of opiate receptors that mediate antinociception in animals.

Authors:  M B Tyers
Journal:  Br J Pharmacol       Date:  1980-07       Impact factor: 8.739

Review 5.  Pros and Cons of Clinically Relevant Methods to Assess Pain in Rodents.

Authors:  Anke Tappe-Theodor; Tamara King; Michael M Morgan
Journal:  Neurosci Biobehav Rev       Date:  2019-03-15       Impact factor: 8.989

6.  Physiological and behavioural effects of the endogenous cannabinoid, arachidonylethanolamide (anandamide), in the rat.

Authors:  E A Stein; S A Fuller; W S Edgemond; W B Campbell
Journal:  Br J Pharmacol       Date:  1996-09       Impact factor: 8.739

7.  Entanglement between thermoregulation and nociception in the rat: the case of morphine.

Authors:  Nabil El Bitar; Bernard Pollin; Elias Karroum; Ivanne Pincedé; Daniel Le Bars
Journal:  J Neurophysiol       Date:  2016-09-07       Impact factor: 2.714

8.  Chlordiazepoxide attenuates response suppression induced by corticotropin-releasing factor in the conflict test.

Authors:  K T Britton; J Morgan; J Rivier; W Vale; G F Koob
Journal:  Psychopharmacology (Berl)       Date:  1985       Impact factor: 4.530

9.  Region-dependent attenuation of mu opioid receptor-mediated G-protein activation in mouse CNS as a function of morphine tolerance.

Authors:  L J Sim-Selley; K L Scoggins; M P Cassidy; L A Smith; W L Dewey; F L Smith; D E Selley
Journal:  Br J Pharmacol       Date:  2007-06-18       Impact factor: 8.739

Review 10.  The Endogenous Cannabinoid System: A Budding Source of Targets for Treating Inflammatory and Neuropathic Pain.

Authors:  Giulia Donvito; Sara R Nass; Jenny L Wilkerson; Zachary A Curry; Lesley D Schurman; Steven G Kinsey; Aron H Lichtman
Journal:  Neuropsychopharmacology       Date:  2017-08-31       Impact factor: 7.853

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.